BIORAY BIOTECH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.55 TWD | -0.18% |
|
+4.36% | -10.84% |
| Apr. 18 | Bioray Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Bioray Biotech Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 826 | 1,290 | 901.1 | 929.6 |
| Enterprise Value (EV) 1 | 741.7 | 1,218 | 862.9 | 902.4 |
| P/E ratio | -14,246 x | -178 x | 1,678 x | -80.4 x |
| Yield | - | - | 0.67% | - |
| Capitalization / Revenue | 5.28 x | 8.72 x | 4.73 x | 4.85 x |
| EV / Revenue | 4.75 x | 8.23 x | 4.53 x | 4.7 x |
| EV / EBITDA | 79.3 x | 229 x | 54.6 x | -544 x |
| EV / FCF | -13.7 x | -211 x | -14.2 x | -70.4 x |
| FCF Yield | -7.32% | -0.47% | -7.03% | -1.42% |
| Price to Book | 2.24 x | 3.55 x | 1.93 x | 2.14 x |
| Nbr of stocks (in thousands) | 26,732 | 26,885 | 30,085 | 30,085 |
| Reference price 2 | 30.90 | 48.00 | 29.95 | 30.90 |
| Announcement Date | 4/27/21 | 4/22/22 | 4/18/24 | 4/18/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 185.5 | 181.9 | 156.3 | 148 | 190.6 | 191.8 |
| EBITDA 1 | 22.48 | 15.25 | 9.356 | 5.32 | 15.79 | -1.659 |
| EBIT 1 | 12.78 | 6.849 | -0.222 | -8.113 | -0.313 | -19.33 |
| Operating Margin | 6.89% | 3.76% | -0.14% | -5.48% | -0.16% | -10.08% |
| Earnings before Tax (EBT) 1 | 22.51 | 21.7 | -1.455 | -6.171 | 0.682 | -14.19 |
| Net income 1 | 21.74 | 19.49 | -0.058 | -7.191 | 0.5 | -11.56 |
| Net margin | 11.72% | 10.71% | -0.04% | -4.86% | 0.26% | -6.03% |
| EPS 2 | 1.000 | 0.7290 | -0.002169 | -0.2700 | 0.0178 | -0.3842 |
| Free Cash Flow 1 | -59.37 | -40.94 | -54.3 | -5.778 | -60.67 | -12.81 |
| FCF margin | -32.01% | -22.5% | -34.75% | -3.9% | -31.83% | -6.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.3648 | 0.3000 | - | - | 0.2000 | - |
| Announcement Date | 1/20/20 | 4/29/20 | 4/27/21 | 4/22/22 | 4/18/24 | 4/18/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 262 | 150 | 84.3 | 72.9 | 38.2 | 27.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -59.4 | -40.9 | -54.3 | -5.78 | -60.7 | -12.8 |
| ROE (net income / shareholders' equity) | 6.12% | 3.58% | -0.38% | -2.16% | 0.12% | -2.61% |
| ROA (Net income/ Total Assets) | 2.08% | 0.88% | -0.03% | -1.08% | -0.04% | -2.12% |
| Assets 1 | 1,044 | 2,210 | 204.2 | 668 | -1,362 | 546 |
| Book Value Per Share 2 | 13.90 | 14.10 | 13.80 | 13.50 | 15.50 | 14.40 |
| Cash Flow per Share 2 | 9.040 | 7.970 | 5.460 | 4.700 | 4.770 | 3.220 |
| Capex 1 | 60.6 | 62.8 | 51 | 15 | 59.6 | 10 |
| Capex / Sales | 32.65% | 34.5% | 32.63% | 10.12% | 31.29% | 5.22% |
| Announcement Date | 1/20/20 | 4/29/20 | 4/27/21 | 4/22/22 | 4/18/24 | 4/18/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -10.68% | 25.47M | |
| +15.27% | 8.27B | |
| +3.37% | 7.47B | |
| -11.26% | 5.23B | |
| -8.69% | 3.62B | |
| -18.20% | 3.26B | |
| -11.27% | 1.22B | |
| -30.34% | 1.06B | |
| -10.34% | 861M | |
| -16.06% | 857M |
- Stock Market
- Equities
- 7561 Stock
- Financials Bioray Biotech Co., Ltd
